Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish plasma specialist

Grifols S.A. shares in Spain remain in focus after the Q1 2026 earnings release and a May uptick in short interest, with investors tracking progress on debt reduction and the plasma-based healthcare group’s positioning on BME and Nasdaq.

Grifols S.A., the Barcelona-based plasma therapeutics group listed on Bolsa de Madrid under the ticker GRF, stays on the radar of Spanish equity investors following its Q1 2026 earnings release on 05/07/2026 and a recent increase in short interest on its Nasdaq-listed shares, keeping attention on leverage, cash generation and sentiment in its home market.

According to coverage of the Q1 2026 results on 05/07/2026, Grifols reported revenue of about EUR 1.7 billion for the quarter, underscoring the continued importance of its plasma-derived medicines and diagnostic activities to the top line while maintaining a stated focus on debt and cash-flow discipline.

On the US market, where the company trades via American Depositary Receipts on Nasdaq under the symbol GRFS, the stock closed at USD 7.85 on 05/29/2026, down 1.63% on the day, while extended trading quoted USD 7.95 later that evening, providing an additional pricing reference alongside the primary Spanish listing.

Short-interest data as of 05/15/2026 show that investors had sold 5,970,653 GRFS shares short, representing approximately 0.88% of the public float and marking a 5.5% increase compared with the previous report, pointing to a measurable but still modest level of bearish positioning around the name.

For investors following the stock from Germany, the shares are also available via trading venues such as Tradegate or Frankfurt, giving euro-based retail investors in the German market an alternative route into the Spanish healthcare group alongside trading on Bolsa de Madrid.

The stock traded at USD 7.85 on 05/29/2026 on Nasdaq, according to MarketBeat data as of 05/29/2026, while the Spanish listing on BME continues to serve as the company’s primary equity reference in its home country.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Grifols
• Sector/industry: Plasma-derived biopharmaceuticals and diagnostics
• Headquarters/country: Barcelona, Spain
• Core markets: Spain, United States, Europe, selected global markets
• Key revenue drivers: Plasma-derived therapies, diagnostic systems and hospital supplies
• Home exchange/listing venue: Bolsa de Madrid (GRF) - ADR: Nasdaq (GRFS)
• Trading currency: EUR for BME listing; USD for Nasdaq ADR

Grifols S.A.: core business model

Operating from its Spanish base, Grifols concentrates on collecting human plasma and turning it into specialized medicines and diagnostic solutions that underpin revenue across its main geographic regions.

What banks and research houses say about Grifols S.A.

While individual bank notes from Spanish brokers are not always publicly accessible, consolidated data from MarketBeat as of 05/29/2026 indicate that Grifols carries a consensus rating and an average price target of USD 10.00 across tracked analysts, implying upside potential versus the USD 7.85 closing level reported for the same date.

According to the same MarketBeat overview as of 05/29/2026, this USD 10.00 target corresponds to an implied upside of roughly 27.4% from the quoted GRFS price, giving a snapshot of how followed sell-side institutions currently frame risk and reward for the plasma-focused group on Nasdaq.

Conclusion

The combination of Q1 2026 revenue of around EUR 1.7 billion and a clear message on debt and cash-flow priorities keeps Grifols in focus on the Spanish market, while the Nasdaq ADR provides a parallel view of investor appetite and liquidity.

Consensus data pointing to an average target of USD 10.00 and a modest but rising short-interest position as of mid-May frame a mixed but engaged backdrop in which both upside scenarios and balance-sheet execution remain closely monitored by market participants on both sides of the Atlantic.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.